
    
      A Phase I, Randomized, Double-Blind, Parallel Group, Study to Assess the Pharmacokinetics and
      Safety of Two Doses of PT010 and a Single Dose of PT003 in Healthy Chinese Adult Subjects
      Following a Single Administration and After Chronic Administration for 7 Days
    
  